Patents by Inventor Sebastian Van Der Woning
Sebastian Van Der Woning has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240026010Abstract: The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).Type: ApplicationFiled: June 7, 2023Publication date: January 25, 2024Inventors: Jean-Michel PERCIER, Christophe Blanchetot, Michael Saunders, Hans De Haard, Sebastian Van Der Woning, Emma Persson, Bart Lambrecht, Savvas Savvides, Hamida Hammad, Kenneth Verstraete
-
Patent number: 11713354Abstract: The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).Type: GrantFiled: March 8, 2021Date of Patent: August 1, 2023Assignees: ARGENX BV, VIB VZW, Universiteit GentInventors: Jean-Michel Percier, Christophe Blanchetot, Michael Saunders, Hans De Haard, Sebastian Van Der Woning, Emma Persson, Bart Lambrecht, Savvas Savvides, Hamida Hammad, Kenneth Verstraete
-
Publication number: 20230088269Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the cytokine receptor IL-22R, particularly human IL-22R. The invention also relates to pharmaceutical compositions comprising said antibodies or antigen binding fragments thereof, and methods of treating psoriasis, psoriatic arthritis or atopic dermatitis.Type: ApplicationFiled: August 11, 2022Publication date: March 23, 2023Inventors: Christophe Frederic Jerome BLANCHETOT, Birgitte URSØ, Tine SKAK-NIELSEN, Malene BERTELSEN, Sebastian VAN DER WONING, Michael SAUNDERS, Johannes Joseph Wilhelmus DE HAARD
-
Patent number: 11447544Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the cytokine receptor IL-22R, particularly human IL-22R. The invention also relates to pharmaceutical compositions comprising said antibodies or antigen binding fragments thereof, and methods of treating psoriasis, psoriatic arthritis or atopic dermatitis.Type: GrantFiled: October 23, 2019Date of Patent: September 20, 2022Assignee: argenx BVInventors: Christophe Frederic Jerome Blanchetot, Birgitte Ursø, Tine Skak-Nielsen, Malene Bertelsen, Sebastian Van Der Woning, Michael Saunders, Johannes Joseph Wilhelmus De Haard
-
Patent number: 11261246Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the cytokine receptor IL-22R, particularly human IL-22R. The invention also relates to pharmaceutical compositions comprising said antibodies or antigen binding fragments thereof, and methods of treating psoriasis, psoriatic arthritis or atopic dermatitis.Type: GrantFiled: October 23, 2019Date of Patent: March 1, 2022Assignee: argenx BVInventors: Christophe Frederic Jerome Blanchetot, Birgitte Ursø, Tine Skak-Nielsen, Malene Bertelsen, Sebastian Van Der Woning, Michael Saunders, Johannes Joseph Wilhelmus De Haard
-
Patent number: 11230603Abstract: The present invention relates to a protein binding to GARP in the presence of TGF-? and uses thereof.Type: GrantFiled: February 14, 2020Date of Patent: January 25, 2022Assignees: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, UNIVERSITÉ CATHOLIQUE DE LOUVAIN, argenx BVBAInventors: Sophie Lucas, Pierre Coulie, Julia Cuende Villasur, Laure Dumoutier, Jean-Christophe Renauld, Sebastian van der Woning, Michael Saunders, Hans De Haard, Gitte De Boeck
-
Publication number: 20210332140Abstract: The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).Type: ApplicationFiled: March 8, 2021Publication date: October 28, 2021Inventors: Jean-Michel PERCIER, Christophe BLANCHETOT, Michael SAUNDERS, Hans DE HAARD, Sebastian VAN DER WONING, Emma PERSSON, Bart LAMBRECHT, Savvas SAVVIDES, Hamida HAMMAD, Kenneth VERSTRAETE
-
Publication number: 20210324061Abstract: The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-?1, particularly a complex of human GARP and human TGF-?1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-? from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.Type: ApplicationFiled: November 12, 2020Publication date: October 21, 2021Inventors: Sebastian van der Woning, Filip Borgions, Torsten Dreier, Lore Mariën, Gitte De Boeck, Stéphanie Liénart, Sophie Lucas, Pierre Coulie
-
Patent number: 11066473Abstract: The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).Type: GrantFiled: April 12, 2019Date of Patent: July 20, 2021Assignees: argenx IIP BV, VIB VZW, Universiteit GentInventors: Jean-Michel Percier, Christophe Blanchetot, Michael Saunders, Hans De Haard, Sebastian Van Der Woning, Emma Persson, Bart Lambrecht, Savvas Savvides, Hamida Hammad, Kenneth Verstraete
-
Patent number: 10875914Abstract: The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-?1, particularly a complex of human GARP and human TGF-?1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-? from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.Type: GrantFiled: May 10, 2019Date of Patent: December 29, 2020Assignees: argenx BVBA, Université Catholique de LouvainInventors: Sebastian van der Woning, Filip Borgions, Torsten Dreier, Lore Mariën, Gitte De Boeck, Stëphanie Liénart, Sophie Lucas, Pierre Coulie
-
Patent number: 10793627Abstract: The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-?1, particularly a complex of human GARP and human TGF-?1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-? from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.Type: GrantFiled: November 27, 2019Date of Patent: October 6, 2020Assignees: argenx BVBA, Université Catholique de LouvainInventors: Sebastian van der Woning, Filip Borgions, Torsten Dreier, Lore Mariën, Gitte De Boeck, Stéphanie Liénart, Sophie Lucas, Pierre Coulie
-
Publication number: 20200216528Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the cytokine receptor IL-22R, particularly human IL-22R. The invention also relates to pharmaceutical compositions comprising said antibodies or antigen binding fragments thereof, and methods of treating psoriasis, psoriatic arthritis or atopic dermatitis.Type: ApplicationFiled: October 23, 2019Publication date: July 9, 2020Inventors: Christophe Frederic Jerome BLANCHETOT, Birgitte URSØ, Tine SKAK-NIELSEN, Malene BERTELSEN, Sebastian VAN DER WONING, Michael SAUNDERS, Johannes Joseph Wilhelmus DE HAARD
-
Patent number: 10696741Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the cytokine receptor IL-22R, particularly human IL-22R. The invention also relates to pharmaceutical compositions comprising said antibodies or antigen binding fragments thereof, and methods of treating psoriasis, psoriatic arthritis or atopic dermatitis.Type: GrantFiled: January 8, 2019Date of Patent: June 30, 2020Assignee: argenx BVBAInventors: Christophe Frederic Jerome Blanchetot, Birgitte Ursø, Tine Skak-Nielsen, Malene Bertelsen, Sebastian Van Der Woning, Michael Saunders, Johannes Joseph Wilhelmus De Haard
-
Publication number: 20200181276Abstract: The present invention relates to a protein binding to GARP in the presence of TGF-? and uses thereof.Type: ApplicationFiled: February 14, 2020Publication date: June 11, 2020Inventors: Sophie Lucas, Pierre Coulie, Julia Cuende Villasur, Laure Dumoutier, Jean-Christophe Renauld, Sebastian van der Woning, Michael Saunders, Hans De Haard, Gitte De Boeck
-
Publication number: 20200157207Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the cytokine receptor IL-22R, particularly human IL-22R. The invention also relates to pharmaceutical compositions comprising said antibodies or antigen binding fragments thereof, and methods of treating psoriasis, psoriatic arthritis or atopic dermatitis.Type: ApplicationFiled: October 23, 2019Publication date: May 21, 2020Inventors: Christophe Frederic Jerome BLANCHETOT, Birgitte URSØ, Tine SKAK-NIELSEN, Malene BERTELSEN, Sebastian VAN DER WONING, Michael SAUNDERS, Johannes Joseph Wilhelmus DE HAARD
-
Patent number: 10604579Abstract: The present invention relates to a protein binding to GARP in the presence of TGF-? and uses thereof.Type: GrantFiled: May 9, 2018Date of Patent: March 31, 2020Assignees: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, UNIVERSITÉ CATHOLIQUE DE LOUVAIN, argenx BVBAInventors: Sophie Lucas, Pierre Coulie, Julia Cuende Villasur, Laure Dumoutier, Jean-Christophe Renauld, Sebastian Van Der Woning, Michael Saunders, Hans De Haard, Gitte De Boeck
-
Publication number: 20200095311Abstract: The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-?1, particularly a complex of human GARP and human TGF-?1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-? from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.Type: ApplicationFiled: November 27, 2019Publication date: March 26, 2020Inventors: Sebastian van der Woning, Filip Borgions, Torsten Dreier, Lore Mariën, Gitte De Boeck, Stéphanie Liénart, Sophie Lucas, Pierre Coulie
-
Publication number: 20190375832Abstract: The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-?1, particularly a complex of human GARP and human TGF-?1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-? from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.Type: ApplicationFiled: May 10, 2019Publication date: December 12, 2019Inventors: Sebastian van der Woning, Filip Borgions, Torsten Dreier, Lore Mariën, Gitte De Boeck, Stéphanie Liénart, Sophie Lucas, Pierre Coulie
-
Publication number: 20190367619Abstract: The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).Type: ApplicationFiled: April 12, 2019Publication date: December 5, 2019Inventors: Jean-Michel PERCIER, Christophe BLANCHETOT, Michael SAUNDERS, Hans DE HAARD, Sebastian VAN DER WONING, Emma PERSSON, Bart LAMBRECHT, Savvas SAVVIDES, Hamida HAMMAD, Kenneth VERSTRAETE
-
Patent number: 10479829Abstract: The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-?1, particularly a complex of human GARP and human TGF-?1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-? from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.Type: GrantFiled: May 11, 2018Date of Patent: November 19, 2019Assignees: argenx BVBA, Université Catholique de LouvianInventors: Sebastian Van der Woning, Filip Borgions, Torsten Dreier, Lore Mariën, Gitte De Boeck, Stéphanie Liénart, Sophie Lucas, Pierre Coulie